Abstract
Lung cancer is the leading cause of malignancy-related mortality worldwide. Metastases, which account for 90% of lung cancer deaths, frequently target the skeleton, leading to rapid deterioration in quality of life and premature death. The molecular mechanism underlying this progression, especially the development of bone metastases, is largely unknown. MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that function as negatively posttranscriptional gene regulators. Changes in miRNAs, which may exhibit either oncogenic or tumor suppressive activity, are common in lung cancer. Over-expressed miRNAs may contribute to oncogenesis by down-regulating tumor suppressors, whereas the loss of selected miRNAs may negatively regulate oncogenes or factors related to tumorigenesis and progression. MiRNAs may activate or repress metastases. Specific miRNA expression profiles may correlate with the response in treatment. We summarize recent findings and patents in the pathological roles of miRNAs in the progression and bone metastases in lung cancer, and discuss the diagnostic and therapeutic options in the clinical management of lung cancer.
Keywords: Biomarker, bone metastases, lung cancer, miRNA, oncogenesis, squamous cell carcinoma.
Recent Patents on Anti-Cancer Drug Discovery
Title:MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Volume: 10 Issue: 2
Author(s): Qian Zhao, Ping Li, Junrong Ma and Xijie Yu
Affiliation:
Keywords: Biomarker, bone metastases, lung cancer, miRNA, oncogenesis, squamous cell carcinoma.
Abstract: Lung cancer is the leading cause of malignancy-related mortality worldwide. Metastases, which account for 90% of lung cancer deaths, frequently target the skeleton, leading to rapid deterioration in quality of life and premature death. The molecular mechanism underlying this progression, especially the development of bone metastases, is largely unknown. MicroRNAs (miRNAs) are small, endogenous, noncoding RNAs that function as negatively posttranscriptional gene regulators. Changes in miRNAs, which may exhibit either oncogenic or tumor suppressive activity, are common in lung cancer. Over-expressed miRNAs may contribute to oncogenesis by down-regulating tumor suppressors, whereas the loss of selected miRNAs may negatively regulate oncogenes or factors related to tumorigenesis and progression. MiRNAs may activate or repress metastases. Specific miRNA expression profiles may correlate with the response in treatment. We summarize recent findings and patents in the pathological roles of miRNAs in the progression and bone metastases in lung cancer, and discuss the diagnostic and therapeutic options in the clinical management of lung cancer.
Export Options
About this article
Cite this article as:
Zhao Qian, Li Ping, Ma Junrong and Yu Xijie, MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (2) . https://dx.doi.org/10.2174/1574892810666150120163617
DOI https://dx.doi.org/10.2174/1574892810666150120163617 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Targeted Therapies for Non-Small Cell Lung Cancer
Current Pharmaceutical Design The Association of Vitamin D Receptor Gene Polymorphism with Lung Cancer Risk: An Update Meta-analysis
Combinatorial Chemistry & High Throughput Screening Synthesis, Biological Evaluation and Docking Studies of 1,3,4-Oxadiazole Fused Benzothiazole Derivatives for Anticancer Drugs
Letters in Drug Design & Discovery IO Nation: The Rise of Immuno-Oncology
Current Pharmacogenomics and Personalized Medicine An Overview of Naturally Occurring Histone Deacetylase Inhibitors
Current Topics in Medicinal Chemistry Regulation of MET Receptor Signaling by SOCS1 and its Implications for Hepatocellular Carcinoma
Current Pharmaceutical Design Cytotoxic Molecules from Natural Sources: Tapping the Brazilian Biodiversity
Anti-Cancer Agents in Medicinal Chemistry Combinatorial Dansyl Library and its Applications to pH-Responsive Probes
Combinatorial Chemistry & High Throughput Screening Gene Therapy in Liver Diseases: State-of-the-Art and Future Perspectives
Current Gene Therapy Decreased Parathyroid Hormone Levels Despite Persistent Hypocalcemia in Patients with Kidney Failure Recovering from Septic Shock
Endocrine, Metabolic & Immune Disorders - Drug Targets Histone Deacetylase Inhibitors in Cancer Therapy: New Compounds and Clinical Update of Benzamide-Type Agents
Current Topics in Medicinal Chemistry Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Immune Checkpoints Aberrations and Malignant Mesothelioma: Assessment of Prognostic Value and Evaluation of Therapeutic Potentials
Anti-Cancer Agents in Medicinal Chemistry Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Crosstalk Between Epidermal Growth Factor Receptor- and Insulin-Like Growth Factor-1 Receptor Signaling: Implications for Cancer Therapy
Current Cancer Drug Targets miRNAs in the Biology of Cancers and Viral Infections
Current Medicinal Chemistry Recent Patents in Toll-like Receptor Pathways and Relevance to Cancer
Recent Patents on Anti-Cancer Drug Discovery The Role and Therapeutic Potential of Ser/Thr Phosphatase PP2A in Apoptotic Signalling Networks in Human Cancer Cells
Current Molecular Medicine The Regulation of Differentiation of Mesenchymal Stem-cells into Skeletal Muscle: A Look at Signalling Molecules Involved in Myogenesis
Current Stem Cell Research & Therapy